šŸ§¬Tidera Health
āš•ļø

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C85

Find Recruiting Clinical Trials for Lymphoma

Search DLBCL, follicular, Hodgkin, and T-cell lymphoma trials ā€” matched to your histology, prior lines, and molecular profile.

šŸ” Search Lymphoma Trials ā†’

About Lymphoma

Lymphoma is a cancer of the lymphatic system, broadly divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). NHL encompasses over 60 distinct subtypes; the most common are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Hodgkin lymphoma has high cure rates with first-line chemoimmunotherapy. NHL outcomes vary dramatically by subtype ā€” DLBCL is potentially curable with R-CHOP, but 30ā€“40% of patients relapse and require salvage therapy, where CAR-T cell therapy has become standard of care.

What Types of Lymphoma Clinical Trials Exist?

Lymphoma trials are among the most active in hematologic oncology. CAR-T cell therapy optimization (axi-cel, liso-cel, tisa-cel), bispecific T-cell engagers (glofitamab, mosunetuzumab, epcoritamab), novel BTK inhibitors, PI3K inhibitors for indolent NHL, PD-1 inhibitor combinations for HL, and ADCs (loncastuximab, polatuzumab vedotin) are all active areas. Histologic subtype, number of prior therapy lines, CAR-T eligibility, and molecular markers (MYC/BCL2 double-hit status, POD24 in follicular lymphoma) determine trial eligibility.

Find Recruiting Lymphoma Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time ā€” matching trials to your age, location, and treatment history. Free, no account required.

Search Lymphoma Trials ā†’

Data from ClinicalTrials.gov Ā· Updated in real time Ā· Educational use only

Frequently Asked Questions

What clinical trials are available for lymphoma?ā–¾
Recruiting lymphoma trials include CAR-T cell therapy optimization, bispecific T-cell engager studies (glofitamab, epcoritamab), ADC combinations (polatuzumab vedotin), BTK inhibitor doublets, novel immunotherapy combinations, and first-line intensification trials for high-risk DLBCL. Hodgkin lymphoma trials test PD-1 inhibitor combinations and de-escalation in favorable disease.
How many prior lines of therapy affect lymphoma trial eligibility?ā–¾
The number of prior treatment lines is the primary stratification variable. First-line trials enroll treatment-naive patients. Relapsed/refractory trials specify minimum prior lines (typically ā‰„1, ā‰„2, or ā‰„3). CAR-T cell therapy is standard of care in ā‰„2 prior lines for DLBCL; post-CAR-T trials enroll patients who progressed after CAR-T. Each relapse generally narrows options while opening access to later-line trials.
What is double-hit lymphoma and why does it matter for trials?ā–¾
Double-hit lymphoma (DHL) is DLBCL with concurrent MYC and BCL2 (or BCL6) gene rearrangements detected by FISH. DHL carries a poor prognosis with standard R-CHOP and is specifically targeted by intensified regimens (DA-EPOCH-R, dose-adjusted EPOCH) and novel combination trials. FISH testing for MYC and BCL2 rearrangement is performed on the diagnostic biopsy sample.

Related Conditions

LeukemiaBreast CancerLung Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.